Side Effects of RAFP Therapy

  • M. Kitahara


There have been many reports in recent years on the effectiveness of combined radiation therapy and chemotherapy in brain tumors, especially malignant gliomas [2, 3,6] and combined radiochemotherapy has become popular. However, although combined therapy accelerates the damage to tumor cells, it also produces deficits in normal tissues and can give rise to acute toxicity due to myelosuppression or gastrointestinal complications. In the present chapter, we report a study of the side effects due to radiation therapy combined with ACNU, FT-207, and PSK (RAFP) therapy.


Malignant Glioma Malignant Brain Tumor Male Female Total Severe Myelosuppression Combine Radiochemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aoki Y (1984) Radiotherapy combined with OK-432 for medulloblastoma and alleviating action of OK-432 on the myelosuppression in mice induced by whole body body irradiation. Proceedings of Japan Cancer Association, The 43rd Annual Meeting, October 3 (Fukuoka), p 457 (in Japanese)Google Scholar
  2. 2.
    Edwards MS, Levin VA, Wilson CB (1980) Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64:1179–1205PubMedGoogle Scholar
  3. 3.
    Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR (1972) The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA 30: 549–552CrossRefGoogle Scholar
  4. 4.
    Kiga M (1965) Radiological approach in fractionated irradiation. Nippon Acta Radiol 24:1283–1285Google Scholar
  5. 5.
    Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237–241PubMedGoogle Scholar
  6. 6.
    Levin VA, Hoffman WF, Pischer TL, Seager ML, Boldrey EB, Wilson CB (1978) BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62:2071–2076PubMedGoogle Scholar
  7. 7.
    Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63:218–223PubMedCrossRefGoogle Scholar
  8. 8.
    Maciejewski B, Preuss-Bayer G, Trott KR (1982) The influence of the number of the fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 8:1471–1489CrossRefGoogle Scholar
  9. 9.
    Phillips GL, Wolf SN, Fay JW (1986) Intensive 1,3-Bis (2-chloroethyl)-l-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncel 4:639–644Google Scholar
  10. 10.
    Saito T, Yokoyama M, Himori T, Ujiie S, Sugawara N, Sugiyama Z, Kitada K (1977) Phase I and phase II study of l-(4-amino-2-methyl-5-pyrimidinyl)methyl-3(2-chloro-ethyl)-3-nitrosourea hydrochloride (ACNU) administered by intermittent dose schedule. Jpn J Cancer Chemother 4:991–1004 (in Japanese)Google Scholar
  11. 11.
    Saito Y, Hori T, Takami M, Muraoka K, Hokama Y, Numata H (1983) The study on postoperative local chemotherapy of malignant brain tumors using ACNU and PSK. Jpn J Cancer Chemother 10:1963–1971 (in Japanese)Google Scholar
  12. 12.
    Thames HD Jr, Peters LJ, Withers HR, Fletcher GH (1983) Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int J Radiat Oncol Biol Phys 9:127–138PubMedGoogle Scholar
  13. 13.
    Ushio Y, Abe H, Suzuki J, Tanaka R, Kitamura K, Miwa T, Matsutani M, Takeuchi K, Takakura K, Nomura K, Yamamoto S, Kageyama N, Handa H, Mogami H, Matsumoto S, Nishimura A, Uozumi T, Hori T, Mori T, Mori K, Matsukado Y (1985) Evaluation of ACNU alone and combined with Tegaful as additions to radiotherapy for the treatment of malignant gliomas—A cooperative clinical trial. Brain and Nerve 37:999–1006 (in Japanese)PubMedGoogle Scholar
  14. 14.
    Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike JA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343PubMedCrossRefGoogle Scholar
  15. 15.
    Walker MD, Green SB, Byar DP, Alexander, E Jr, Batzorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMedCrossRefGoogle Scholar
  16. 16.
    Weir B, Band P, Urtasun R, Blain G, Mclean D, Wilson F, Mielke B, Grace M (1976) Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 45:129–134PubMedCrossRefGoogle Scholar
  17. 17.
    Weiss RB, Muggia FM (1980) Cytotoxic drug-induced pulmonary disease; Update 1980. Am J Med 68:259–266PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1988

Authors and Affiliations

  • M. Kitahara

There are no affiliations available

Personalised recommendations